期刊文献+

表达水痘-带状疱疹病毒糖蛋白E基因毕赤酵母的构建 被引量:2

Construction of recombinant Pichia pastoris yeast expressing glycoprotein E of the varicella-zoster virus
原文传递
导出
摘要 目的本研究拟将水痘-带状疱疹病毒(varicella-zoster virus,VZV)的主要抗原糖蛋白E在酵母表达系统中分泌表达。方法根据酵母的密码子偏爱性优化编码VZV糖蛋白E的基因后,构建真核表达载体p GAPZαA-g E,并将其转化至毕赤酵母X-33菌株中进行摇瓶表达,利用SDS-PAGE以及Western-blot鉴定其蛋白表达情况。结果经检测,在筛选得到的重组子p GAPZαA-g E/X-33摇瓶表达上清中可检测到相对分子质量约为60×103的目的蛋白条带。结论实现了水痘-带状疱疹病毒糖蛋白E基因在毕赤酵母中的分泌表达,为进一步制备水痘-带状疱疹病毒糖蛋白E、研究其免疫原性及疫苗的研发等相关性研究奠定了基础。 Objective To construct a recombinant yeast to express secretory glycoprotein E of varicella-zoster virus(VZV)in the yeast strain Pichia. Methods The DNA sequence encoding glycoprotein E of VZV was optimized for Pichia pastoris.Then,the sequence was synthesized and cloned into eukaryotic expression vector pGAPZαA.The recombinant plasmid was isolated,linearized,and transformed into the X-33 strain of the yeast Pichia pastoris by electroporation.After selection,target protein in the culture supernatant was examined by SDS-PAGE and Western blot. Results Both SDS-PAGE and Western blot results proved the expression of glycoprotein E(60×103)in the fermentation supernatant of transformants pGAPZαA-gE/X-33. Conclusions A recombinant yeast was successfully constructed to express secretory VZV-gE in the yeast strain Pichia.
作者 吴克 王雨 高媛 毛普加 刘昊智 李津 肖杨 WU Ken;WANG Yu;GAO Yuan;MAO Pu-jia;LIU Hao-zhi;LI Jin;XIAO Yang(Bravovax Co. ,Ltd, Wuhan , Hubei 430075, Chin)
出处 《中国病毒病杂志》 CAS 2018年第1期21-25,共5页 Chinese Journal of Viral Diseases
基金 武汉市应用基础研究计划项目(2016060101010038)
关键词 水痘-带状疱疹病毒 糖蛋白 毕赤酵母 真核表达 Varicella-zoster virus Glycoprotein Pichia pastoris Eukaryotic expression
  • 相关文献

参考文献3

二级参考文献46

  • 1Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster [J]. J Clin Virol, 2010, 48(Suppl 1): S2-S7.
  • 2Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM. Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells [J]. J Virol, 2011, 85(9): 4095-4110.
  • 3Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeli:re P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults [J]. J Infect Dis, 2012, 206(8): 1280-1290.
  • 4Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales [J]. Vaccine, 2001, 19 (23-24): 3076-3090.
  • 5Gauthier A, Breuer J, Carrington D, Martin M, R6my V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom [J]. Epidemiol Infect, 2009, 137(1): 38-47.
  • 6Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, Farrara A. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission [J]. JAMA, 1984, 252(3): 355-362.
  • 7Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+T cells [J]. J Infect Dis, 2006, 194(2): 247-255.
  • 8Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review [J]. J Infect Dis, 2008, 197(Suppl 2) : S224-S227.
  • 9Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand [J]. J Infect Dis, 2008, 197 (Suppl 2) : S191-S195.
  • 10Centers for Disease Control and Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) FS/OL]. http://www, cdc. gov/MMWr/preview/mmwrhtml/rr5604al, htm.

共引文献28

同被引文献9

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部